A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
A Multi-center, Placebo-controlled, Double Blind Multiple-ascending Dose Study in a Leapfrog Design to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of RO5024118 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients 40-70 years of age, inclusive.
- Body Mass Index 18-32 kg/m2, inclusive.
- Female patients must be surgically sterile or post menopausal for the past year confirmed by a negative hormone panel. Male patients and their partners of childbearing potential must use two methods of contraception, one of which must be a barrier method for the duration of the study and for 7 days after last dose.
- Diagnosis of moderate-to-severe COPD (GOLD Stage II-III).
Exclusion Criteria:
- Current smoker or history of smoking in the last three months.
- Use of continuous daily long term oxygen therapy or requirement for oxygen therapy during exercise.
- History of cardiac conduction abnormalities or ventricular tachyarrhythmias.
- Exacerbation of COPD within 8 weeks before first dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
|
escalating inhaled dose
|
|
EXPERIMENTAL: 2
R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
|
escalating inhaled dose
|
|
EXPERIMENTAL: 3
R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
|
escalating inhaled dose
|
|
EXPERIMENTAL: 4
R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
|
escalating inhaled dose
|
|
EXPERIMENTAL: 5
R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
|
escalating inhaled dose
|
|
EXPERIMENTAL: 6
R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
|
escalating inhaled dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To investigate the safety and tolerability of multiple inhaled doses of R7103 as compared to placebo, and to define the Maximum Tolerated Dose (MTD) in target population
Time Frame: 18 days per arm
|
18 days per arm
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NP22131
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.